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We generated mice deficient in Lon protease
(LONP1), amajor enzyme of themitochondrial quality
control machinery. Homozygous deletion of Lonp1
causes early embryonic lethality, whereas its hap-
loinsufficiency protects against colorectal and skin
tumors. Furthermore, LONP1 knockdown inhibits
cellular proliferation and tumor and metastasis for-
mation, whereas its overexpression increases tumor-
igenesis. Clinical studies indicate that high levels of
LONP1 are a poor prognosis marker in human colo-
rectal cancer and melanoma. Additionally, functional
analyses show that LONP1 plays a key role in
metabolic reprogramming by remodeling OXPHOS
complexes and protecting against senescence. Our
findings demonstrate the relevance of LONP1 for
cellular and organismal viability and identify this pro-
tease as a central regulator of mitochondrial activity
in oncogenesis.INTRODUCTION
Mitochondria are subcellular organelles of eukaryotic cells
responsible for generating the bulk of cellular energy in the
form of ATP through oxidative phosphorylation (OXPHOS; Fried-
man and Nunnari, 2014). Mitochondria are also involved in other
pathways of intermediate metabolism, generate and regulate
reactive oxygen species (ROS), maintain homeostasis and cal-
cium buffering, and participate in essential cellular processes
such as apoptosis (Wallace et al., 2010). Consistent with the
wide diversity of functional roles played by these organelles,
mitochondrial dysfunctions are associated with aging and path-
ological processes such as cancer and neurological diseases542 Cell Reports 8, 542–556, July 24, 2014 ª2014 The Authors(Lo´pez-Otı´n et al., 2013; Wallace, 2005). To exert their functions
properly, mitochondria have developed a quality control system
composed of proteases and chaperones that regulate the
assembly, folding, and turnover of proteins, as well as the
removal of damaged proteins (Tatsuta, 2009). In mammals, there
are fourmajor ATP-dependent proteases that participate inmito-
chondrial quality control: Yme1 and m-AAA proteases localized
in the inner membrane, and ClpP and Lon located in the matrix
(Rugarli and Langer, 2012). Additionally, there are several ATP-
independent proteases that collaborate inmitochondrial homeo-
stasis (Cipolat et al., 2006; Quiro´s et al., 2012).
Lon protease (LONP1) is a conserved serine peptidase that
contributes to protein quality control processes from bacteria
to eukaryotic cells (Lu et al., 2003). LONP1 plays an important
role in the degradation of misfolded and damaged proteins,
and supports cell viability under oxidative, hypoxic, and endo-
plasmic reticulum-stress conditions (Venkatesh et al., 2012).
There are several proposed substrates for this enzyme in mam-
mals, such as aconitase, cytochrome c oxidase isoformCOX4-1,
steroidogenic acute regulatory protein, and 5-aminolevulinic
acid synthase (Bota and Davies, 2002; Fukuda et al., 2007;
Granot et al., 2007; Tian et al., 2011). LONP1 is also a DNA-bind-
ing protein that participates in mtDNA maintenance and gene
expression regulation (Liu et al., 2004). Moreover, LONP1 de-
grades mitochondrial transcription factor A (TFAM), regulating
mtDNA copy number and metabolism to maintain the TFAM/
mtDNA ratio necessary to control replication and transcription
(Lu et al., 2013; Matsushima et al., 2010).
Consistent with the crucial role of LONP1 in the control ofmito-
chondrial function under stress conditions, changes in the
expression levels of this protease gene are associated with
several human diseases (Venkatesh et al., 2012). Moreover,
LONP1 levels are increased in different tumors and tumor cell
lines (Bernstein et al., 2012; Hu et al., 2005; Kita et al., 2012).
Interestingly, downregulation of LONP1 in some tumor cells
causes apoptosis and cell death (Bota et al., 2005), indicating
a possible addiction of tumor cells to LONP1 function, as occurs
with other intracellular proteases associated with cancer (Fraile
et al., 2012; Freije et al., 2011).
To further analyze the in vivo roles of this mitochondrial prote-
ase in both normal and pathological conditions, including
cancer, we have generated mutant mice deficient in Lonp1.
Homozygous deletion of Lonp1 causes early embryonic lethality
but Lonp1+/ heterozygous mice are fertile and viable, thereby
facilitating cancer susceptibility studies that have shown that
these haploinsufficient animals are protected against colon
and skin carcinomas induced by chemical carcinogens. More-
over, knockdown of Lon protease in colorectal and melanoma
cells inhibits in vivo tumor growth and metastasis, respectively,
whereas LONP1 overexpression promotes tumorigenesis.
Finally, we provide evidence that LONP1 regulates metabolic re-
programming and controls tumor bioenergetics by remodeling
OXPHOS complexes.
RESULTS
Lonp1 Deletion Causes Embryonic Lethality in Mice
Mice heterozygous for the targeted allele of themitochondrial Lon
protease (Lonp1+/) were viable and fertile with no obvious abnor-
malities. These mice were intercrossed to generate homozygous
mice deficient in Lonp1 (Figure S1A). However, we did not detect
homozygous pups at weaning (Figure S1B), suggesting that
Lonp1 homozygous deletion causes embryonic lethality. To
further assess this hypothesis, we analyzed and genotyped em-
bryos at different stages of development, from 3.5 to 9.5 days
postcoitum (dpc). We found that at blastocyst stage (3.5 dpc),
the number of embryos of the different genotypes followed the ex-
pected Mendelian ratios. However, at 8.5 dpc, only one of the
analyzed viable embryos carried the homozygous mutation,
whereas at 9.5 dpc none of them carried the mutation in homozy-
gosis (Figures 1A and S1B). Moreover, analysis of nonviable
mutant embryos at 8.5 dpc showed a clear reduction in size
when compared with their littermate controls, looking like
7.5 dpc embryos and suggesting that their development was
arrested.Thesedifferencesweremaintainedat9.5dpc (Figure1A).
To clarify the embryonic lethality of Lonp1/, we performed
comparative histological analysis of embryos from both geno-
types. Lonp1/ embryos from 5.5 and 6.5 dpc showed normal
size and development (Figure 1B). However, at 7.5 dpc, Lonp1
null embryos showed a marked growth decrease, being much
smaller than their littermate controls and exhibiting incomplete
formation of embryo cavities, thereby pointing to a developmental
arrest at the egg-cylinder early gastrulation stage (Figure 1B).
To further characterize the cause of lethality observed in
Lonp1 null embryos, we first tried to generate ES cells or murine
embryonic fibroblasts with homozygous deletion of Lonp1. How-
ever, after repeated experiments, we were unable to obtain any
Lonp1-deficient cell line. To evaluate the putative relationship
between mtDNA deficiencies and embryonic lethality in Lonp1
null mice, we analyzed mtDNA copy number in Lonp1-null
embryos during development. We observed that at 3.5 dpc,
there were no differences between control, heterozygous, and
Lonp1 null embryos (Figure 1C). However, analysis at 7.5 dpc
showed a decrease in mtDNA copy number in Lonp1-deficientembryos compared with control and heterozygous embryos
(Figure 1C). To further evaluate the influence of LONP1 defi-
ciency in embryo development, we analyzed the in vitro growth
of embryos. We isolated preimplantation embryos by uterine
flushing at the blastocyst stage (3.5 dpc). As shown in Figures
1D and S1B, almost all blastocysts obtained from intercrossed
heterozygousmicewere normal and viable, and Lonp1-null blas-
tocysts were indistinguishable from the corresponding controls.
We then cultured blastocysts for 5 days in embryonic stem cell
media, finding that virtually all analyzed embryos developed nor-
mally. However, Lonp1-deficient embryos showed a smaller size
in the inner cell mass and trophoblast cells compared with litter-
mates (Figure 1E). Taken together, these results indicate that
LONP1 is essential for in vivo and in vitro embryo development.
Embryonic absence of this protease leads to marked growth
retardation and arrest likely due to mitochondrial dysfunction
and loss of mtDNA, with subsequent failure to accomplish the
energy requirements necessary for embryonic development.
In marked contrast to embryonic lethality of Lonp1/ mice,
Lonp1+/ animals developed normally and did not display any
obvious pathological alterations. Analysis of Lonp1 expression in
heterozygous mice indicated a 50% reduction at both RNA and
protein levels in these animals (Figures 1F and 1G). These findings
demonstrate that LONP1 haploinsufficiency is compatible with
embryonic and adult mouse development, as well as with normal
growth and fertility, thus opening the possibility to perform long-
term studies of cancer susceptibility in Lonp1+/ mice.
Lonp1-Haploinsufficient Mice Are Protected against
Colorectal Cancer and Chemically Induced Skin Tumors
To analyze the role of LONP1 in tumor development, we induced
colon carcinoma in Lonp1+/ and Lonp1+/+ mice, using azoxy-
methane (AOM) and dextrane sulfate (Figure 2A). All Lonp1
wild-type mice, but only 72% Lonp1 heterozygous mice, devel-
oped colorectal tumors (Figure 2B). Moreover, Lonp1+/ mice
had significantly fewer tumors than control animals (Figures 2C
and 2D). There was also a decrease in the colon length in
Lonp1 control mice compared with heterozygous mice (Fig-
ure 2E). Quantitative analysis of the clinical score during the
carcinogenesis protocol revealed that Lonp1+/ mice exhibited
milder clinical features than wild-type animals (Figure 2F).
To characterize the putative role of LONP1 in tumor develop-
ment, we used an additional carcinogenesis protocol to induce
skin tumors. We subjected Lonp1-heterozygous mice and their
wild-type littermate controls to a 7,12-dimethylbenzanthracene
and tetradecanoylphorbol acetate (DMBA/TPA) protocol that in-
duces skin papillomas. Lonp1 heterozygous mice developed
significantly fewer and smaller papillomas during the treatment
and displayed a significantly lower incidence of the appearance
of papillomas (Figures 2G–2I). These results indicate that LONP1
has a key role in the development of colon and skin tumors, and a
decrease in Lonp1 levels protects against colorectal carcinoma
and papilloma formation in mice.
LONP1 Is Upregulated in Colon Cancer and Promotes
Tumor Growth
To clarify the role of this mitochondrial protease in colorectal
cancer, we studied LONP1 expression in different humanCell Reports 8, 542–556, July 24, 2014 ª2014 The Authors 543
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Figure 1. Lonp1 Deletion Causes Embryonic Lethality
(A) Representative images of Lonp1+/+ and Lonp1/embryos at 8.5 and 9.5 dpc. Scale bar represents 1mm. Right: PCR analysis of Lonp1 embryos’ genotypes.
(B) Histological analysis of embryos from 5.5 to 7.5 dpc of control and Lonp1-deficient embryos. EX, extraembryonic part; EM, embryonic part; epc, ectoplacental
cavity; exc, exocoelomic cavity; ac, amniotic cavity. Scale bar represents 100 mm.
(C) Analysis of mtDNA quantity expressed as a percentage of levels in control embryos at 3.5 dpc and 7.5 dpc embryos. Data are presented as mean ± SEM
(n = 10–20), **p < 0.01.
(D) Representative images of blastocysts (3.5 dpc embryos) obtained after heterozygous intercrosses of Lonp1 mice.
(E) Lonp1-null embryos showed reduced size and delayed development in vitro compared with control blastocysts. ICM, inner cell mass; TB, trophoblastic cells.
Scale bar represents 50 mm.
(F) qPCR and (G) western blot analysis of LONP1 expression in murine embryonic fibroblasts derived from Lonp1+/+ and Lonp1+/mice. qPCR data are presented
as RQ value ± SD, **p < 0.01.
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colorectal cancer cell lines (HCT116, HCT15, HT29, SW480,
SW620, DLD-1, and RKO), and in a colon epithelial cell line
(FHC). Quantitative PCR and western blot analysis showed a
high expression of LONP1 in all colon cancer cell lines compared
to the control epithelial colon cells (Figures 3A and 3B). To
analyze the relevance of Lon protease in these colon carcinoma
cells, we usedHCT116 cells to perform in vitro and in vivo studies
of loss- and gain-of-function. We reduced Lon protease levels
using lentiviral-based shRNAs against LONP1, and ectopically
induced LONP1 using a retroviral system that expresses a
Flag-tagged LONP1 cDNA construct. The expression of
LONP1was confirmedwith qPCR andwestern blot analysis (Fig-
ures 3C and S2A). Knockdown of LONP1 (shLon) significantly
reduced cell proliferation in vitro compared to control cells
(pLKO1; Figures 3D and S2B). However, ectopic expression of
LONP1 (LON) did not increase proliferation when compared to
control cells (pMX; Figure 3D). Likewise, overexpression of
LONP1 in DLD-1, a colon cancer cell line with low levels of
LONP1 expression, did not increase the proliferation rates (Fig-
ure S2C). We then examined the in vivo relevance of LONP1
expression on tumor growth, using a xenograft model. As shown
in Figure 3E, tumor growth of shLon cells was significantly
reduced when compared to pLKO1 control cells. On the other
hand, ectopic expression of LONP1 increased growth of tumors
in nude mice compared to those generated by pMX control cells
(Figure 3F). These results indicate that LONP1 is necessary to
maintain the proliferative rates and tumor growth of this colo-
rectal cancer cell line.
To further evaluate the relevance of LONP1 expression in
colon carcinoma, we performed an immunohistochemical anal-
ysis of human samples from normal and tumor colorectal sec-
tions. In agreement with previous data, LONP1 is expressed in
normal colon samples and highly upregulated in colon cancer
mucosa (Figure 3G). Moreover, analysis of transcriptional data
from colorectal adenomas and normal mucosa showed a signif-
icant increase in LONP1 expression in adenomas compared to
their matched normal mucosa (Figure 3H). Detailed analysis of
reported data on survival of patients with Duke’s stages A–C
colorectal carcinoma showed a positive correlation between
high LONP1 expression and lower survival (Figure 3I). Collec-
tively, these results suggest that Lonp1 upregulation is common
in colorectal cancer and may provide some advantage to tumor
cells, thereby facilitating cancer development.
LONP1 Is Necessary for Proliferation and Metastasis of
Melanoma Cells
As described above, Lonp1-heterozygous mice displayed less
susceptibility to develop tumors than control mice. Analysis of
human cutaneous melanoma, showed a significant increase in
LONP1 levels in melanoma compared to normal skin or benign
nevi samples (Figure 4A). Moreover, analysis of clinical outcome
of patients with metastatic melanoma showed a positive correla-
tion between LONP1 expression and short survival (Figure 4B).
To further evaluate the functional relevance of Lon protease in
tumor and metastasis formation in vivo, we used the murine
B16F10 melanoma cells in which we reduced LONP1 levels
using lentiviral-based shRNA and induced ectopic expression
of LONP1 using a retroviral system. A complete set of shRNA(shLon) reduced both LONP1 mRNA and protein levels approx-
imately 90% compared with control pLKO1 shRNA, whereas
ectopic expression of Lon increased the levels of protein and
mRNA 10-fold (Figures 4C, 4D, and S3A). Knockdown of
LONP1 diminished in vitro proliferation of B16F10 cells, whereas
ectopic expression of LONP1 did not increase proliferation rates
(Figures 4E and S3A). We then analyzed the in vivo formation of
experimental lung metastasis using this highly metastatic mela-
noma cell line. As shown in Figure 4F, knockdown of LONP1
reduced 10-fold the number of metastasis compared to pLKO1
control cells. Conversely, overexpression of Lon protease in-
creased significantly the number of metastasis (Figure 4G).
These results indicate that LONP1 is essential for cell prolifera-
tion as well as for metastasis formation in vivo, and high levels
of LONP1 are a marker of poor prognosis in human melanoma.
LONP1 Induces a Metabolic Switch and Regulates
Tumor Bioenergetics by Remodeling OXPHOS
Complexes
To study the role of LONP1 in the regulation of mitochondrial
function in cancer, we used the above described B16F10 mela-
noma cells with knockdown or overexpression of Lon protease.
Thesemelanoma cells are wild-type for BRAF, indicating that the
mitochondrial activity and respiration are important and the
energy production is not shifted to glycolysis (Castle et al.,
2012; Haq et al., 2013). Knockdown of LONP1 decreased cellular
ATP content, whereas ectopic expression of LONP1 increased
ATP content (Figures 5A and S4A). Furthermore, analysis of
mitochondrial respiration showed a decrease in basal oxygen
consumption in LONP1 ablated cells when compared to controls
(Figures 5B and S4B). Interestingly, overexpression of Lon
protease also showed a decrease in mitochondrial respiration
compared to control cells (Figure 5B). Stimulation with the
chemical uncoupler trifluorocarbonylcyanide phenylhydrazone
increased oxygen consumption to maximal respiration rate in
both pLKO1 and pMX control cells. Nevertheless, neither knock-
down nor overexpression of Lon protease reached similar oxy-
gen consumptions than control cells (Figures 5B and S4B). In
addition, both knockdown and ectopic expression of LONP1
increased the glucose consumption and lactate production
compared to controls (Figures 5C, 5D, S4C, and S4D). These re-
sults were puzzling because both conditions, i.e., ablation and
overexpression of LONP1, induce the downregulation of respira-
tion and the upregulation of the glycolytic pathway. To try to
understand this phenomenon, we examinedmitochondrial respi-
ratory complexes and detected a significant decrease in com-
plex I (Figures 5E and S4E) and a concomitant decrease in
complex III-containing supercomplexes (Figures 5F and S4E) in
shLon cells. Similarly, we observed a significant decrease
in complex I, II, and IV in cells overexpressing LONP1 (Figures
5G and S4F), as well as a reduction in complex III-containing
supercomplexes (Figures 5H and S4F). We also noticed that
the relative amount of complex V in dimers was reduced in
both models (Figures 5F and 5H). The observed decrease in
mitochondrial complexes in both models likely derives from
enhanced degradation or from a reduction in their assembly
and could underlie the decrease in mitochondrial respiration in
both LONP1-overexpressing and LONP1-deficient cells.Cell Reports 8, 542–556, July 24, 2014 ª2014 The Authors 545
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Figure 2. Lonp1+/Mice Display Less Susceptibility to Azoxymethane-Induced Colon Tumors and Skin Chemical Carcinogenesis Induced by
DMBA/TPA
(A) Scheme of azoxymethane-induced colon tumor protocol.
(B) Percentage of animals with tumors (p < 0.05).
(C) Average of tumors observed in Lonp1+/+ and Lonp1+/ mice.
(legend continued on next page)
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We next evaluated the individual activities of mitochondrial
complexes by spectrophotometric analysis of mitochondria iso-
lated from both cells. We observed that shLon cells showed
significantly lower activities of complex I (CI) and combined com-
plex II+complex III (CII+III) activity (Table S1), consistent with the
low levels of CI and assembled CIII measured by BNGE (Figures
5E and 5F). In contrast, overexpression of LONP1 decreased
almost all individual complex activities. Thus, we observed a
reduction in CII and complex IV (CIV), as well as combined CI+III
and CII+III activities (Table S1), consistent with the general
decrease in almost all complexes observed by BNGE (Figures
5G and 5H). Moreover, knockdown of Lon protease specifically
induced an increased activity of CI+III relative to CI (CI+III/CI)
and decreased activity of CII+III relative to CII (CII+III/CII)
(Figure 5I), suggesting that complex III is more dedicated to
complex I than to complex II, favoring the use NADH equivalents
and the respiration through complex I. However, overexpression
of Lon protease showed a decrease in the activity of CI+III
relative to CI (CI+III/CI), which indicated a reduction in the
respiration through complex I, while respiration efficiency
through complex II (CII+III/CII) remained unaltered (Figure 5J).
Collectively, the changes observed in the LONP1-overexpress-
ing cells are consistent with a metabolic reprogramming of the
OXPHOS system by primarily reducing the flux from NADH
electrons (more catabolic), but maintaining the flux through the
FAD-dependent enzymes, that are also involved in anabolic
(nucleotide and amino acid metabolism) and detoxifying meta-
bolic pathways. Nevertheless, the changes in respiration flux
observed in shLon cells are more closely related to a catabolic
metabolism.
To further clarify the differences observed in the regulation of
OXPHOS complexes in LONP1-overexpressing and LONP1-
knockdown cells, we performed a quantitative proteomic anal-
ysis, using iTRAQ labeling and subsequent LC-MS/MS analysis.
As an internal control of our analysis, we found a significant in-
crease in LONP1 protein levels in the overexpression model,
whereas this protease was undetectable in the downregulation
model (Figure 5K). Consistent with the above findings in
OXPHOS complex levels, we detected a significant alteration
in the amount of complex I proteins in both LONP1-overexpress-
ing and LONP1-knockdown cells (Figure 5K). However, the
affected complex I protein components differed between both
cells, suggesting a distinct mechanism of regulation in each
condition. Thus, all CI proteins were downregulated in LONP1-
knockdown cells, while they presented variability in LONP1-
overexpressing cells, some of them being upregulated and other
downregulated. Furthermore, CI structural proteins, such as
NDUFB6, 8, 10 and 11, were the more downregulated proteins
in LONP1-knockdown cells, while they were upregulated in
LONP1-overexpressing cells. Importantly, these proteins are(D) Representative images of hematoxylin and eosin staining of colon sections fr
resents 200 mm.
(E) Measurement of the length of the colon at the end of the experiment.
(F) Clinical score throughout the experiment based on stool consistency and rec
(G) Average number of papillomas per mouse grouped by size (diameter of the l
(H) Inverse Kaplan-Meier analysis of the percentage of mice with papillomas. Lo
(I) Representative pictures of papilloma lesions of Lonp1+/+ and Lonp1+/ at weeassociated with the assembly and stability of the CI membrane
domains and are required for their activity (Andrews et al.,
2013; Perales-Clemente et al., 2010). Conversely, among the
most decreased proteins in the LONP1-overexpressing cells,
there were four subunits of the NADH dehydrogenase and hy-
drogenase catalytic modules of CI, such as NDUFV1, NDUFV2,
NDUFS3, and NDUFS7. Interestingly, it has been described
that these proteins can be removed and replaced in the complex
I without degrading the whole complex (Dieteren et al., 2012;
Lazarou et al., 2007). These results indicate that the observed
complex I decrease in shLon cells was a consequence of loss
of stability of this complex, whereas in LONP1-overexpressing
cells the decrease was functional, maintaining the structural
domains. Moreover, complex V subunits were clearly downregu-
lated in shLon cells (Figure 5K), which is in line with the observed
decrease in complex V dimers (Figure 5F). Interestingly, LONP1-
overexpressing cells showed an increase in complex V subunits
(Figure 5K), despite the observed decrease in dimers (Figure 5H),
which indicates that these cells have a different complex V
regulation.
Overall, these data strongly suggest that the apparent
convergence in the decrease in aerobic respiration and the
subsequent glycolysis activation, by either knockdown or
overexpression of LONP1, takes place through different mech-
anisms. The loss of mitochondrial complexes would operate
in shLon cells, whereas OXPHOS complexes remodeling
would underlie the alterations found in LONP1-overexpressing
cells.
LONP1 Keeps Mitochondrial Function and Induces a
Global Metabolic Reprogramming
To further clarify the observed alterations in LONP1-overex-
pressing and LONP1-knockdown cells, we analyzed other
parameters related to mitochondrial function in these cells. We
first found that LONP1-knockdown, but not its overexpression,
induced a decrease in both mitochondrial membrane potential
(Figure 6A) and mtDNA content (Figure 6B). shLon cells also dis-
played an increase in mitochondrial fragmentation (Figures 6C
and S5A) and ROS production (Figure 6D), which caused the
proteolytic processing of OPA1 (Figures 6E and S5B). These
findings are indicative of a clear mitochondrial dysfunction,
which is not observed in LONP1-overexpressing cells. More-
over, knockdown of Lon protease activated the AMPK pathway
(Figure 6E), which is in line with the low ATP levels and the mito-
chondrial stress scenario observed in these cells. In contrast,
overexpression of LONP1 decreased AMPK activation (Fig-
ure 6E). In addition, and consistent with the enhancement of
the glycolytic pathway detected in both LONP1-overexpressing
and LONP1-knockdown cells, there was an increase in the
expression of glycolytic genes in both cases (Figure S5C).om Lonp1+/+ and Lonp1+/ mice at the end of the experiment. Scale bar rep-
tal bleeding. Data are presented as mean ± SEM (n = 11–14), *p < 0.05.
esion in millimeters), and represented for each genotype (n = 10).
g-rank test p = 0.0439.
k 18. Scale bar represents 200 mm.
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However, analysis of lipid synthesis showed a significant
decrease in shLon cells, which agrees with the AMPK activation
in these cells, whereas LONP1-overexpressing cells displayed
similar rates than control cells (Figures 6F and S5D). Interest-
ingly, and despite that we did not detect differences in apoptosis
(data not shown), we found increased levels of the antiapoptotic
protein Bcl-2 in LONP1-overexpressing cells and decreased
levels in shLon cells (Figure 6E), which suggests a possible in-
crease in apoptosis sensitivity in LONP1-deficient cells. We
next examined in both LONP1-overexpressing and LONP1-
knockdown cells the levels and activity of aconitase (ACO2), a
well-established substrate for Lon protease. We found a
decrease in ACO2 activity in LONP1-overexpressing cells and
an increased activity of this enzyme in shLon cells (Figure S5E).
The low expression levels of ACO2 in these cells precluded the
detection of clear differences in enzyme levels. However, after
transfection of a cDNA encoding ACO2, we detected increased
levels and activity of this enzyme in control cells, but not in
LONP1-overexpressing cells (Figures S5F and S5G), indicating
that LONP1 processes ACO2 under conditions where this sub-
strate is highly expressed.
Taken together, these results indicate that the absence
of LONP1 induces a generalized mitochondrial dysfunction,
whereas its overexpression does not alter the mitochondrial
homeostasis. To further characterize the cellular alterations
induced by the depletion and overexpression of LONP1, we per-
formed quantitative proteomic analysis of the corresponding
cells and found that LONP1 overexpression increased the levels
of proteins related with protein synthesis, such as eukaryotic
translation initiation factor complex 3 and ribosomal proteins
(Figure 6G). We also found increased levels of proteins related
to the spliceosome, proteasome, and chaperone-containing T
complex (Figure 6H), which is consistent with the increased
tumorigenesis observed in LONP1-overexpressing cells. Con-
versely, LONP1-deficient cells showed reduced levels of all of
these proteins (Figures 6G and 6H), which agrees well with the
low proliferation rate and tumorigenic potential of these cells.
These data illustrate the occurrence of marked differences in
the process of metabolic adaptation after modulation of
LONP1 levels, which leads to a profound mitochondrial dysfunc-
tion when cells are depleted of Lon protease and to a global
metabolic remodeling when this mitochondrial enzyme is
overexpressed.Figure 3. LONP1 Is Upregulated in Colon Cancer Cell Lines and Colore
(A) qPCR analysis of LONP1 expression in colon cancer cell lines, normalized to
(B) Western blot analysis and densitometry quantification of LONP1 expression
(C) Western blot and densitometry quantification of HCT116 colon cancer cells
control (pLKO1), as well as with pMX expressing murine LONP1 (LON) and the em
endogenous and flagged transgene.
(D–F) MTT analysis showed decreased proliferation in shLon HCT116 cell lines w
Tumor xenograft experiments were carried out using HCT116 cells and compa
overexpressing cells versus pMX control cells. Tumor volume was calculated fo
differences were assessed with a linear mixed-effects model; data are presented
(G) Immunohistochemical analysis of LONP1 expression in normal and tumor co
(H) Relative expression of LONP1 extracted from a previously reported comparativ
the same individuals (GEO accession number GDS2947) (Sabates-Bellver et al.,
(I) Kaplan-Meier survival curves for 64 patients with colorectal cancer expressin
GSE14333 (Jorissen et al., 2009).LONP1 Contributes to Bypass Oncogene-Induced
Senescence
LONP1 knockdown induces growth arrest and mitochondrial
dysfunction in melanoma cells, impairing mitochondrial respira-
tion and causing loss of mitochondrial integrity. Interestingly, we
also observed that shLon cells displayed an increase in size
compared with control pLKO1 or LONP1-overexpressing cells,
suggesting the occurrence of a cellular senescence phenotype
(Figure 7A). Moreover, b-galactosidase staining (a marker of
senescent cells) showed an increased positivity in cells lacking
Lonp1, whereas overexpression of LONP1 decreased the num-
ber of b-galactosidase positive cells (Figure 7B). The induction
of cellular senescence is mainly mediated by signals derived
from a permanent DNA damage response. Accordingly, we
found that the loss of mitochondrial integrity caused by LONP1
deficiency induced a DNA damage response likely mediated
by p53, as assessed by the increased levels of direct transcrip-
tional targets of this tumor suppressor (Figure 7C). Interestingly,
knockdown of LONP1 in p53-deficient cells resulted in lower
proliferation defects when compared to wild-type cells, indi-
cating that p53 contributes to the observed alterations (Fig-
ure 7D). Overexpression of LONP1 in B16F10 cells reduced the
levels of these markers and b-galactosidase activity (Figures
7B and 7D), indicating a protection against senescence by Lon
protease, which was consistent with the tumorigenic increase
of these melanoma cells.
On the other hand, it is well established thatmutations inHRAS
or BRAF also induce a senescence phenotype, known as onco-
gene-induced senescence (OIS), as part of a cell response
against tumor transformation (Michaloglou et al., 2005; Serrano
et al., 1997). Based on this information, we explored available
cancer transcriptome databases looking for putative differences
in LONP1 expression levels during OIS processes. Thus, by
analyzing data from previous studies involving transformation
of fibroblasts with mutant MEK, we found that induced OIS did
not promote changes in LONP1 expression. However, bypassing
senescence in these fibroblasts using viral oncoproteins signifi-
cantly increased LONP1 expression (Figure 7E), further support-
ing the idea that upregulation of Lon protease may favor onco-
genic transformation. These results demonstrate that LONP1 is
essential to protect against senescence, and reinforce the pro-
posal that levels of this serine protease contribute to modulate
the tumorigenic properties of cancer cells.ctal Tumors and Promotes Tumorigenesis In Vivo
colon epithelial cells and represented with a RQ value ± SD.
in the same colon cancer cell lines.
transduced with LONP1 shRNA vectors (shLon) or with the empty vector as a
pty vector (pMX). LONP1 values correspond to the concomitant expression of
hen compared to control cells; data are presented as mean ± SEM, *p < 0.05.
ring (E) shLon transduced cells versus pLKO1 control cells and (F) LONP1-
r each group at the indicated times after cancer cell injection, and significant
as mean ± SEM (n = 7), *p < 0.05.
lon human samples.
e data set of transcriptomes of 32 adenomas and those of normal mucosa from
2007). Data are presented in box-and-whisker plot format.
g high (top 25% of patients) and low (bottom 25% of patients) LONP1 levels.
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Figure 5. LONP1 Controls Tumor Bioenergetics by Remodeling OXPHOS Subunits
(A–K) B16F10 melanoma cells with knockdown (shLon) and overexpression (LON) of Lon protease and their respective controls pLKO1 and pMX were used to
study OXPHOS function. (A) Relative ATP levels of the analyzed cells. (B) Oxygen consumption rate (OCR) in basal conditions and after stimulation with tri-
fluorocarbonylcyanide phenylhydrazone, MRR (maximal respiration rate), represented as OCR per cell relative to each control cell. (C) Percentage of glucose
consumption and (D) lactate production during 48 hr, relative to control cells. BNGE quantification of OXPHOS subunits (RC complex) using TOM20 as a loading
control of isolated mitochondria from (E) shLon and (G) LON cells, relative to each control. BNGE quantification of complexes contained in SC relative to complex
free of isolated mitochondria from (F) shLon and (H) LON cells, relative to each control. Combined mitochondrial complex activities relative to free complexes to
assess the use of NADH (CI+III/CI) or FAD electron equivalents (CII+III/CII) in (I) shLon cells and (J) LON cells. All experiments were independently carried out at
least three times, using triplicates for each cell line; data are presented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. (K) Heatmap showing protein
abundance changes in Lon protease and subunits of CI and CV, obtained with high-throughput quantitative proteomics of enriched mitochondrial preparations.
The relative abundance changes in LON and shLon cells are expressed using the Z score in relation to each control. ND, not determined.DISCUSSION
We describe herein the generation and phenotypic characteriza-
tion of mice deficient in the mitochondrial Lon protease, as wellFigure 4. LONP1 Expression Is Essential for Tumor Development and
(A) Relative expression levels of LONP1 in normal skin, benign nevi, andmelanoma
whisker plot format.
(B) Kaplan-Meier survival curves for 27 patients with metastatic melanoma expres
GSE19234 (Bogunovic et al., 2009).
(C and D) Analysis of LONP1 levels in B16F10-luc2 cells after lentiviral transduction
as after retroviral transduction of LON protease (LON) and empty vector pMX, fo
represented with a RQ value ± SD. LONP1 levels in the overexpressing cells we
(E) MTT analysis showed a decrease in proliferation in shLon B16F10-luc2 cell li
(F and G) Total number of lung metastasis, generated in the left lung, using pLK
overexpression of Lon protease (LON). Data are presented as mean ± SEM (n = 1
the end of each experiment.as the functional analysis of this ATP-dependent enzyme con-
trolling tumor bioenergetics. We found that mice deficient in
LONP1 show a lethal phenotype during gastrulation, a period
in which a well-fitted mitochondrial function is required to induceMetastasis Formation
from data set GDS1375 (Talantov et al., 2005). Data are presented in box-and-
sing high (top 25% of patients) and low (bottom 25% of patients) LONP1 levels.
with a control pLKO1 empty vector and shRNA against Lonp1 (shLon) as wells
llowed by western blot analysis with densitometry quantification and (D) qPCR
re the cumulative values of endogenous and flagged construct expression.
nes. Data are presented as mean ± SEM, **p < 0.01.
O1 control and shLon B16F10-luc2 melanoma cells, and (G) pMX control and
0), *p < 0.05, ***p < 0.001. (F and G; bottom) Representative images of lungs at
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Figure 6. LONP1 Maintains Mitochondrial Function and Promotes a Metabolic Remodeling Process
(A–H) B16F10 melanoma cells with knockdown (shLon) and overexpression of Lon protease (LON) and their respective controls pLKO1 and pMX were used to
study mitochondrial function. (A) Mitochondrial membrane potential (DJm) represented as a percentage of TMRM fluorescence, in normal cells and after
carbonyl cyanide m-chlorophenyl hydrazoneP treatment. (B) mtDNA levels represented as percentage relative to each control. (C) Percentage of fragmented
mitochondria quantified after mtDsRed2 transfection. (D) ROS levels represented as relative levels of DCF-DA fluorescence. (E) Western blot analysis showing
processing of OPA1 long isoforms (a and b) and increase in the short isoforms (c to e), AMPK activation, and Bcl2 decrease in shLon cells. Overexpression of LON
causes reduced AMPK activity and an increase in Bcl2 levels. (F) Fatty acid synthesis rate measured as 14C incorporation into cellular lipids represented as
relative units (RU). All experiments were independently carried out at least three times, using triplicates for each condition; data are presented as mean ± SEM,
*p < 0.05, ***p < 0.001. Heatmap showing abundance changes of proteins belonging to the eukaryotic translation initiation factor 3 (Eif3) and the ribosomal
complexes (G), and to the spliceosome, the proteasome and the chaperone-containing T (CCT) complex (H), obtained with high-throughput quantitative pro-
teomics of whole-cell lysates. The relative abundance changes in LON and shLon cells are expressed using the Z score in relation to each control.profound changes in embryo development (Nagy et al., 2003). At
this stage, Lonp1 null embryos display loss of mtDNA and
growth arrest, which are features observed in mice deficient in
OXPHOS complex subunits, like GRIM19 and SCO2 (Huang
et al., 2004; Yang et al., 2010), or in mtDNA-associated proteins,
such as POLG, POLG2, and TFAM (Hance et al., 2005; Humble
et al., 2013; Larsson et al., 1998), that also exhibit embryonic
lethality. In contrast, Lonp1-heterozygous mice develop nor-
mally, allowing us to evaluate in vivo the functional and patho-
logical relevance of LONP1 haploinsufficiency. Interestingly,
Lonp1+/ mice are protected against chemically induced colo-
rectal and skin tumors, suggesting an oncogenic function for
this mitochondrial protease. Consistent with this hypothesis,
LONP1 is upregulated in human colorectal and skin carcinomas
and their levels are associated with poor clinical outcome of the
corresponding patients. Accordingly, LONP1-knockdown in
colorectal cancer cells reduces in vitro cell proliferation and552 Cell Reports 8, 542–556, July 24, 2014 ª2014 The Authorsin vivo growth of tumors derived from these cells, whereas
ectopic expression of LONP1 increases tumor growth. More-
over, overexpression of LONP1 in melanoma cells increases
experimental metastasis formation, whereas knockdown of
this protease decreases cell proliferation and lung metastasis.
Notably, LONP1 upregulation does not stimulate cell prolifera-
tion, despite the observed increase in tumor growth and metas-
tasis in vivo. The metabolic and stress adaptations undergone
by cancer cells during the tumorigenesis process, which are
not perfectly replicated in the in vitro experiments, may explain
these differences, also observed in similar studies involving
other metabolic genes with oncogenic function (Bhalla et al.,
2011). Accordingly, we propose that the upregulation of
LONP1 observed in many cancer cell lines and tumor samples
(Bernstein et al., 2012; Hu et al., 2005), is probably the conse-
quence of an adaptive metabolic response during malignant
transformation.
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Figure 7. LONP1 Is Necessary to Bypass Oncogene-Induced Senescence
(A) Brightfield images of B16F10 melanoma cells. Scale bar represents 100 mm.
(B) Percentage of cells positive for b-galactosidase activity as a measure of cellular senescence. Data are presented as mean ± SEM, *p < 0.05, ***p < 0.001.
(C) Transcriptional qPCR analysis of p53-target genes (Atf3, Gadd45 g, and Cdkn1a/p21) in these melanoma cells. Data are shown as RQ value ± SD, *p < 0.05.
(D) MTT analysis of p53-deficient and wild-type fibroblasts after knockdown of LONP1. The decrease in Lon protease in a background deficient in p53 has less
effect than in wild-type background.
(E) LONP1 relative expression levels in control, senescence-induced, and senescence-bypassed fibroblasts extracted from the data set GSE2484 (Collado et al.,
2005). ***p < 0.001.
(F) Model summarizing the functional relevance of Lon protease in reprogramming mitochondrial activity in cancer.Metabolic reprogramming of tumor cells has been recently
established as a hallmark of cancer (Hanahan and Weinberg,
2011). Several enzymes have been proposed to act as protu-
morigenic factors and contribute to this metabolic reprogram-
ming (Chae et al., 2012; Vazquez et al., 2013). Furthermore,
mutations in genes encoding mitochondrial and metabolic en-
zymes have been widely reported in humanmalignancies (Rodrı´-
guez et al., 2013; Yan et al., 2009), indicating that tumor cells
harbor genetic alterations that affect metabolic function and
facilitate tumor formation. The main feature of this reprogram-
ming process is the switch from oxidative to glycolytic meta-
bolism (Vander Heiden et al., 2009). Curiously, we have found
that both upregulation and knockdown of Lon protease in mela-
noma cells induce the same glycolytic switch, turning cells from
oxidative to anaerobicmetabolism. In this regard, it is well estab-
lished that upregulation of the glycolytic pathway during tumor
transformation is triggered by oncogenic signals, such as acti-
vating mutations in the oncogene BRAF in melanoma, as well
as by many physiological and pathological conditions which
cause metabolic changes (Metallo and Vander Heiden, 2013;
Wallace et al., 2010). Additionally, a glycolytic shift is also
induced by impairment of the mitochondrial respiratory chain(Hu et al., 2012). This impairment of mitochondrial OXPHOS trig-
gers glycolytic metabolism as a survival mechanism that often
endswith cell collapse due to the inability of these damaged cells
to reprogram their metabolism (Wallace, 2005). Accordingly, the
glycolytic switch observed in cells lacking LONP1 may be an
obligate consequence of their mitochondrial dysfunction, not
being related to metabolic reprogramming of cancer cells.
Conversely, the switch observed in LONP1-overexpressing cells
is a mitochondria-controlled mechanism, which forms part of a
generalized metabolic reprogramming that contributes to the
development and progression of cancer.
The metabolic adaptation of shLon cells induces a change in
respiration and in the use of electron equivalents, favoring the
utilization of NADH electron equivalents feeding CI, which sug-
gests the occurrence of a catabolic phenotype (Lapuente-Brun
et al., 2013). However, the decrease in supercomplexes due to
loss of specific structural subunits implies that this is not a regu-
lated mechanism, but a consequence of defective assembly or
mitochondrial membrane destabilization. In addition, the subse-
quent loss of membrane potential and the alterations in complex
V cause a decrease in ATP generation, whereas the increase in
ROS levels exacerbates this mitochondrial dysfunction. TheseCell Reports 8, 542–556, July 24, 2014 ª2014 The Authors 553
stress conditions induce the OPA1 processing and mitochon-
drial fragmentation events that may contribute to the decrease
in respiration and functional supercomplexes assembly (Cogliati
et al., 2013). Moreover, the loss of mitochondrial membrane
potential may inhibit the entry of pyruvate into mitochondria
(Herzig et al., 2012), reducing the Krebs cycle function and the
generation of essential metabolites for cell viability. Conse-
quently, the decrease in ATP levels and the mitochondrial stress
signals induce AMPK activation, which downregulates anabolic
pathways, such as lipid synthesis, and upregulates catabolic re-
actions, such as glycolysis, to try to counteract this stress
scenario. However, despite the activation of all these stress-
response mechanisms, shLon cells are unable to avoid mito-
chondrial dysfunction due to the dramatic alterations present
in them. Accordingly, the mitochondrial dysfunction in shLon
cells activates a genetic damage response, likely mediated by
p53, which finally triggers cell cycle arrest and senescence.
This response mechanism induced by mitochondrial damage
reinforces the role of LONP1 as a guardian against reduced
cellular and organismal fitness by contributing to maintain mito-
chondrial integrity.
Conversely, the glycolytic switch observed in LONP1-overex-
pressing cells is triggered by a regulated metabolic reprogram-
ming, maintaining other mitochondrial functions unaltered. The
upregulation of LONP1 induces a remodeling of mitochondrial
complexes and supercomplexes, decreasing the mitochondrial
respiration and favoring the metabolic switch because, under
these conditions, respiratory reactions shift toward the glycolytic
pathway (Wallace, 2012). Moreover, Lon protease overexpres-
sion reduces the use of NADH equivalents and the respiration
through CI, which is frequently mutated and inactivated in tumor
cell lines (Santidrian et al., 2013). However, despite the reduction
of levels and activity of mitochondrial complexes, LONP1 also in-
creases the stability of the CI basic structure. This conversion in-
dicates that the inactivation is regulated and that remodeling
could maintain the ability to activate the respiration to increase
metabolic flexibility when it is required, a mechanism that has
been proposed in other similar contexts (Dieteren et al., 2012).
Lon protease appears to be a key factor in metabolic reprog-
ramming through remodeling of mitochondrial function, support-
ing the idea that steady-state alterations of this ATP-dependent
protease have a significant impact on respiratory chain activity
(Figure 7F). This function is consistent with previous studies
showing that LONP1 degrades COX4-1 in response to HIF1a
and leads to the exchange of this subunit with COX4-2, which
is more effective under hypoxic conditions (Fukuda et al.,
2007). Recent studies have also shown that Lon protease over-
expression upregulates the CI subunit NDUFS8 and generates a
more aggressive phenotype in cancer cells (Cheng et al., 2013).
All of these data illustrate the essential roles of LONP1 in the
regulation of mitochondrial and OXPHOS function in tumor cells.
We have also observed that metabolic reprogramming pro-
moted by LONP1 enhances protein synthesis and metabolism
and activates different pathways that may contribute to the
observed aggressiveness of cancer cells overexpressing
LONP1. Nevertheless, because the Lon protease is also
increased in response to other stress stimuli (Hori et al., 2002),
it is likely that additional proteolytic processing events associ-554 Cell Reports 8, 542–556, July 24, 2014 ª2014 The Authorsated with these stress responses may also contribute to the
increased tumorigenesis caused by upregulation of this enzyme.
Furthermore, the increase in LONP1 expression after bypass of
OIS highlights the importance of Lon protease in tumor transfor-
mation and mitochondrial metabolic reprogramming. Hence,
LONP1 emerges as an indispensable protease for cellular life,
also being necessary for tumor growth due to its ability to main-
tain and modulate mitochondrial activity.
In summary, the generation of Lonp1-deficient mice has
allowed us to identify the essential roles of this mitochondrial
protease in cell and organismal viability. Additionally, the identi-
fication of LONP1 as a key metabolic factor affecting mitochon-
drial reprogramming and tumor bioenergetics may open away to
develop cancer therapies. These results confirm the importance
of studying genetic and metabolic alterations in tumor cells, in
order to rationalize an effective response to anticipate the devel-
opment of cancer.
EXPERIMENTAL PROCEDURES
Generation of Lonp1/ Mice and Genotyping
The Lonp1-heterozygous mice were provided by Texas Institute for Genomic
Medicine (Figure S1A). We used genomic DNA from tail samples for PCR gen-
otyping under the following conditions: denaturation at 94C for 15 s, anneal-
ing at 62C for 15 s, and extension at 72C for 45 s, 30 cycles. We used the
following primers for genotyping: wild-type-specific forward 50-ccctgactgca
gagattgtgaa-30, mutation-specific forward 50-caggacatagcgttggctacc-30, and
common reverse 50-ttcagtgccagtgccttagagt-30.
Animal Studies and Carcinogenesis Protocols
All animal procedures were approved in accordance with the guidelines of
the Committee for Animal Experimentation of the Universidad de Oviedo.
Xenograft studies were performed as described (Fraile et al., 2013). Colon
and skin carcinogenesis, and lung metastasis were induced as reported
(Balbı´n et al., 2003; Gutie´rrez-Ferna´ndez et al., 2008; Neufert et al., 2007).
Complete methods can be found in the Supplemental Experimental
Procedures.
Cell Culture
Cancer cell lines 293T, HCT116, HCT15, HT29, SW480, SW620, DLD-1, RKO,
and FHC were purchased from the American Type Culture Collection. The
luciferase-expressing cell line B16F10 Luc2 was purchased from Caliper Life
Sciences. Cells were routinely maintained in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum, 100 U/ml penicillin, and
100 mg/ml streptomycin (Life Technologies).
DNA Constructs
Mouse cDNA from LONP1 was cloned tagged with a FLAG epitope in the car-
boxy terminus and subcloned into the pMX retroviral vector. The construct was
verified by capillary sequencing. For RNA interference experiments, five
shRNA vectors were purchased for human and mouse LONP1 (RHS4533-
NM_004793 for human and RMM4534-NM_028782 for mouse; Open Bio-
systems, Thermo Scientific).
Seahorse Analysis of Mitochondrial Function
Oxygen consumption was measured in 2 3 104 intact cells using a Seahorse
Bioscience XF96 extracellular flux analyzer, following the manufacturer’s in-
structions. Briefly, after a 12 min equilibration, three measurements of 3 min
were performed, separated by 3 min of mixing. Maximal membrane potential
was assessed with the addition of 1 mM oligomycin, and uncoupled mito-
chondrial respiration was induced with injection of 1 mM carbonyl cyanide
m-chlorophenyl hydrazone. To stop the mitochondrial-dependent oxygen
consumption, both 1 mM rotenone and antimycin were used.
Statistical Analysis
All experimental data are reported asmeans and the error bars represent SEM.
Differences between mean values were analyzed with two-tailed Student’s
t test, except in the cases that indicate use of another statistical test. A p <
0.05 was considered significant and statistically significant differences are
shown with asterisks. All statistical analyses were done using LibreOffice or
the statistical package R (http://www.r-project.org/) and the application
Rstudio (http://www.rstudio.org).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.06.018.
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